Hepatitis B Virus (HBV) Therapeutics – Current and Future Players

GlobalData has released its pharma report, “Hepatitis B Virus (HBV) Therapeutics – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HBV Market. The report identifies and analyses the key companies shaping and driving the global HBV market. The report provides insight into the competitive HBV landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Investigation of current and future market competition for HBV

Competitor assessment

Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.

Strategic assessment of HBV sector through market impact analysis, future market scenario and company analysis

Reasons to buy

Gain a high level view of the trends shaping and driving HBV market

Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

Create an effective counter-strategy to gain a competitive advantage against those currently in the market

What’s the next big thing in the global HBV market landscape? Identify, understand and capitalize

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Market Outlook

3.1Global Markets

3.1.1Forecast

3.1.2Drivers and Barriers – Global Issues

4Current and Future Players

4.1Overview

4.2Trends in Corporate Strategy

4.3Company Profiles

4.3.1Gilead

4.3.2Bristol-Myers Squibb

4.3.3Roche

4.3.4Merck

4.3.5GSK

4.3.6Novartis

4.3.7Arrowhead Research

4.3.8GlobeImmune

5Appendix

5.1Bibliography

5.2Abbreviations

5.3Methodology

5.4Forecasting Methodology

5.4.1Total Prevalent Cases of Chronic Hepatitis B

5.4.2Diagnosed Chronic Hepatitis B Patients

5.4.3Percent Drug-Treated Chronic Hepatitis B Patients

5.4.4Drugs Included in Each Therapeutic Class

5.4.5Launch and Patent Expiry Dates

5.4.6General Pricing Assumptions

5.4.7Individual Drug Assumptions

5.4.8Generic Erosion

5.4.9Pricing of Pipeline Agents

5.5Primary Research – KOLs Interviewed for this Report

5.6Primary Research – Prescriber Survey

5.7About the Authors

5.7.1Analyst

5.7.2Therapy Area Director

5.7.3Epidemiologists

5.7.4Global Director of Therapy Analysis and Epidemiology

5.7.5Global Head of Healthcare

5.8About GlobalData

5.9Disclaimer

List of Tables

Table 1: Global Sales Forecasts ($m) for Chronic Hepatitis B Therapeutics, 2014–2024

Table 2: Chronic Hepatitis B Therapeutics Market – Drivers and Barriers, 2014–2024

Table 3: Key Companies in the Chronic Hepatitis B Therapeutics Market, 8MM, 2015

Table 4: Gilead’s Chronic Hepatitis B Portfolio Assessment, 2015

Table 5: BMS’s Chronic Hepatitis B Portfolio Assessment, 2015

Table 6: Roche’s Chronic Hepatitis B Portfolio Assessment, 2015

Table 7: Merck’s Chronic Hepatitis B Portfolio Assessment, 2015

Table 8: GSK’s Chronic Hepatitis B Portfolio Assessment, 2015

Table 9: Novartis’ Chronic Hepatitis B Portfolio Assessment, 2015

Table 10: Arrowhead’s Chronic Hepatitis B Portfolio Assessment, 2015

Table 11: GlobeImmune’s Chronic Hepatitis B Portfolio Assessment, 2015

Table 12: Key Historical and Projected Launch Dates

Table 13: Key Historical and Projected Patent Expiry Dates

Table 14: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Sales for Chronic Hepatitis B Therapeutics by Country, 2014–2024

Figure 2: Sales for Chronic Hepatitis B Therapeutics by Therapy Class, 2014–2024

Figure 3: Company Portfolio Gap Analysis in the Chronic Hepatitis B Therapeutic Market, 2014–2024

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports